Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial. (2022)

First Author: Amuge P

Attributed to: Blood borne viruses funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s2352-3018(22)00163-1

PubMed Identifier: 36055295

Publication URI: http://europepmc.org/abstract/MED/36055295

Type: Journal Article/Review

Volume: 9

Parent Publication: The lancet. HIV

Issue: 9

ISSN: 2352-3018